Introduction
• In patients with diabetes, poor glycemic control is associated with increased morbidity, mortality, and health care costs.
1,2,3
• GLP-1 receptor agonists (GLP-1RA) have been shown to reduce HbA1c in patients with uncontrolled type 2 diabetes mellitus (T2DM). 4, 5 • There is limited data on once-weekly or once-daily GLP-1RA realworld outcomes in patients with uncontrolled or poorly controlled diabetes who are initiated on a GLP-1RA without prior insulin treatment.
Objectives
• Evaluate glycemic response to GLP-1RA therapy in insulin-naïve patients with T2DM at 6 and 12 months of follow up • Report HbA1c outcomes in a subset of poorly controlled patients with HbA1c ≥9% 
Limitations
• Unmeasured confounders including diet and exercise were not included in the analysis due to data limitations. • Prescription data was based on prescription order and the patient may not have filled the prescription; actual adherence may have confounded the results.
Conclusions
• GLP-1RA treatment was associated with a significant and sustained reduction in HbA1c up to 12 months in insulin-naïve patients with uncontrolled T2DM in a real-world setting; HbA1c reduction was twice the overall average in the subset with baseline HbA1c ≥9%.
• GLP-1RAs may be considered in insulin-naïve patients with poorly controlled T2DM.
